Protein misfolding pathway

Protein misfolding pathways refer to the cellular mechanisms that recognize and manage proteins which have failed to achieve their correct three-dimensional structure. Proper folding is essential for a protein’s function; when this process fails—due to genetic mutations, environmental stressors such as pH or temperature changes, oxidative damage, or errors in posttranslational modification—proteins can become dysfunctional and aggregate into toxic forms[1][5][6]. Cells employ several major systems to clear these potentially harmful species: • The **ubiquitin-proteasome pathway** tags misfolded proteins with ubiquitin for targeted degradation by the proteasome[2]. • **Autophagy** engulfs larger aggregates or damaged organelles within autophagosomes that fuse with lysosomes for breakdown[2]. • Additional mechanisms include direct lysosomal uptake and newly discovered vesicle-mediated routes that shuttle nuclear/cytoplasmic debris into degradative compartments[4]. Failure in these clearance processes leads to accumulation of toxic aggregates implicated in neurodegenerative diseases such as Alzheimer’s disease (beta‑amyloid), Parkinson’s disease (alpha‑synuclein), Huntington’s disease (huntingtin), and prion disorders. These aggregates disrupt organelle function, block normal degradation machinery, trigger cellular stress responses like unfolded protein response (UPR), and ultimately cause cell death[1][6][8]. While “protein misfolding pathway” describes a set of biological processes rather than a single molecular target such as an enzyme or receptor—and thus is not considered a canonical therapeutic target itself—it represents an important area for drug development aimed at enhancing clearance capacity or preventing aggregate formation. Note on correctness: “Protein misfolding pathway” is not the name of a discrete molecule/receptor but rather refers collectively to multiple interconnected cellular processes. For structured databases focused on molecular targets suitable for pharmacological intervention lists—such as receptors or enzymes—a more precise entry would be individual components like “Ubiquitin-proteasome system,” “Autophagy-related gene 5,” etc.[2][4]

Other names

Protein misfoldingMisfolded protein clearance pathwaysProtein quality control pathways

Enhancement or modulation of degradation pathways (e.g., proteasome activators, autophagy inducers) Inhibition of protein aggregation (e.g., small molecules targeting amyloid formation)